Knowledge Tree
Relations (1)
related 0.50 — strongly supporting 5 facts
Psilocybin is the primary pharmacological agent used in psychedelic-assisted psychotherapy, as evidenced by the formalized treatment models described in [1], [2], and [3]. The procedure for this therapy specifically involves the administration of psilocybin during the dosing phase to facilitate the therapeutic experience, as detailed in [4] and [5].
Facts (5)
Sources
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org 5 facts
procedureThe Montreal model protocol for ketamine treatment involves six relatively brief ketamine infusions over a period of 4 weeks, which differs from the one or two longer psilocybin sessions typically employed in other psychedelic-assisted psychotherapy (PAP) studies.
claimThe most common approach to psilocybin-assisted psychotherapy involves one or two high doses of psilocybin, distinguishing it from the 'psycholytic' approach (smaller doses with frequent psychotherapy sessions) and microdosing (regular use of subperceptual doses without psychotherapy).
procedureThe treatment (or dosing) phase of psilocybin-assisted psychotherapy involves patients undergoing approximately 6-hour psilocybin experiences, once or twice, while receiving psychological support from clinicians in comfortable, de-medicalized environments.
claimPsychedelic-assisted psychotherapy models for psilocybin are more formalized and better supported by clinical research than equivalent models for ketamine.
claimPsychedelic-Assisted Psychotherapy (PAP) is generally understood as a synergistic mind–body intervention conducted in three phases: preparatory sessions, one to two doses of psilocybin administered with attention to set and setting alongside non-directive psychological support, and post-experience integration.